ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Nearly 2 years after launching from David Baker’s lab at the University of Washington’s Institute for Protein Design, Vilya Therapeutics expanded its series A financing round by $21 million, to $71 million raised. Vilya has so far used its computational platform to identify macrocyclic peptides that can bind to multiple proteins (Science 2024, DOI: 10.1126/science.adk1687). The new investment, whose funders include Arch Venture Partners and the venture arm of the tech company Nvidia, will be used to ready these peptides for testing in humans, Vilya says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter